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Abstract
Objective: To assess the budgetary impact of switching from screen-film mammography to full-field digital mammography
in a population-based breast cancer screening program.
Methods: A discrete-event simulation model was built to reproduce the breast cancer screening process (biennial
mammographic screening of women aged 50 to 69 years) combined with the natural history of breast cancer. The
simulation started with 100,000 women and, during a 20-year simulation horizon, new women were dynamically entered
according to the aging of the Spanish population. Data on screening were obtained from Spanish breast cancer screening
programs. Data on the natural history of breast cancer were based on US data adapted to our population. A budget impact
analysis comparing digital with screen-film screening mammography was performed in a sample of 2,000 simulation runs. A
sensitivity analysis was performed for crucial screening-related parameters. Distinct scenarios for recall and detection rates
were compared.
Results: Statistically significant savings were found for overall costs, treatment costs and the costs of additional tests in the
long term. The overall cost saving was 1,115,857J (95%CI from 932,147 to 1,299,567) in the 10th year and 2,866,124J
(95%CI from 2,492,610 to 3,239,638) in the 20th year, representing 4.5% and 8.1% of the overall cost associated with screen-
film mammography. The sensitivity analysis showed net savings in the long term.
Conclusions: Switching to digital mammography in a population-based breast cancer screening program saves long-term
budget expense, in addition to providing technical advantages. Our results were consistent across distinct scenarios
representing the different results obtained in European breast cancer screening programs.
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Introduction
In Spain, all resident women aged 50–69 are actively invited to
participate in the population-based breast cancer screening
program by written letter every 2 years. A screening mammogram
(a type of low-dose x-ray examination used to detect breast cancer)
is offered, allowing women who begin screening at 50–51 years up
to a maximum of 10 screening mammograms. Breast cancer
screening in Spain adheres to the European Guidelines for Quality
Assurance in Mammographic Screening [1] and its results meet
the required standards [2,3].
Several studies have shown that digital mammography is more
expensive than screen-film mammography [4–7], requires a
considerable initial financial outlay and that the cost reimburse-
ment of the switch is marginal. Previous studies have also
emphasized the benefits of the technical features of digital
mammography: the image is visualized in a computer window
instead of a hard copy, which precludes film processing, storage,
copying and retrieval. These benefits revert at the logistic level
within a screening program: mammograms are visualized, stored
and retrieved more easily, and allow radiologists to manipulate the
image (such as zooms or changes of brightness and contrast)
without additional exposure of the woman to radiation and
attendance to the hospital. Digital equipment was approved by the
US Food and Drug Administration based on results showing
similar efficacy to conventional mammography [8]. The European
guidelines for breast cancer screening recognize that digital
mammography is likely to become established due to its
advantages [1]. However, the cost-effectiveness of this switch in
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population-based screening programs, which involve millions of
women and millions of tests, is controversial and, to our
knowledge, no budget impact analysis has been performed to date.
In Spain, screening units are increasingly switching to digital
mammography as a consequence of digitalization of radiology
departments. The US Preventive Services Task Force recommen-
dations [9], however, were based on the results of screening with
screen-film mammography and consider that there is insufficient
evidence to recommend digital mammography. The existing
evidence on the effect of digital mammography in population-
based breast cancer screening programs indicators is inconclusive:
although the latest studies have found a slightly higher detection
rate (number of cancers detected per 1,000 examinations) with
digital mammography [10], the main conclusion of review studies
is that digital mammography is at least as good as screen-film [11–
13]. Recent studies in Spain [14–16] have found a lower recall rate
(percentage of women called back for further tests) for digital
mammography and a similar cancer detection rate. In contrast,
other studies have found significantly higher recall rates with
digital mammography [17,18]. Further recent findings indicate the
number of invasive procedures is lower with digital mammography
[16,19] and that the tumoral characteristics detected [16,20] and
interval cancer (primary breast cancer arising after a negative
screening episode and before the next invitation to screening or
within 24 months for women who reached the upper age limit)
rates [21] are similar.
Budget impact analysis aims to estimate the impact of
introducing a new technology in the budgets for the coming years
[22–25]. According to Mauskopf et al. [22], this type of analysis
measures the impact of a new technology on the annual cost and
annual health benefit, as well as other outcomes of interest, in the
years after its introduction in a national health system or a private
health plan. For the time being, Budget Impact Analysis has had a
short run in the scientific literature since the format used generally
consisted in simple models based on assumptions from the
literature and often on expert opinion. In recent years several
authors have proposed guidelines for its development with more
stringent requirements and have provided the scientific status to
Budget Impact Analysis [22–25]. This type of analysis is especially
important when assessing population-based programs in which
small variations may affect a substantial proportion of the
population.
In light of current findings, the economic impact of switching to
digital mammography needs to be assessed. This impact includes
not only the costs of mammography itself, but also the costs
derived from performing a population-based screening program
involving millions of women and tests, i.e., the costs of additional
diagnostic tests and those of cancer treatment. The objective of the
present study was to estimate the long-term impact on costs and
health outcomes of switching from screen-film mammography to
full-field digital mammography in a population-based breast
cancer screening program from the perspective of a National
Health System.
Methods and Materials
Ethics Statement
This study was approved by the ethics committee of Hospital del
Mar. The need for written informed consent was waived because
all data was analyzed anonymously.
Discrete-event simulation model
Discrete-event simulation has been defined as ‘‘a flexible
modeling method characterized by the ability to represent
complex behavior within, and interactions between individuals,
populations, and their environments’’ [26]. A discrete-event
simulation model was built to reproduce the process of women
entering a population-based breast cancer screening program. The
events simulated were as follows: inclusion of a new woman in the
target population, participation in the screening program, a
positive or negative result of screening (including screening
mammography and additional tests), nonscreening cancer detec-
tion, exit from the target population, and death. The conceptual
model was based on the European guidelines [1] and is depicted in
Figure 1.
Parallel to the events related to the screening program, each
woman was assigned a natural history of breast cancer. These
events consisted of the start of the pre-clinical stage (when the
cancer appears but it is asymptomatic), the start of the clinical
stage (when the cancer is symptomatic), and death (Fig. 1). The
model allowed for the absence of progression but did not consider
spontaneous cancer remission.
The time units were years. A simulated time horizon of 20 years
(from 2010 to 2029) was chosen to encompass the life history of a
woman entering a screening program (from 50 to 69 years) and to
allow the budget impact to be analyzed in the long term.
Individual women were simulated. Two identical groups of
women with the same pattern of screening participation were
simulated: one group by using the parameters estimated for
screen-film mammography and the other by using parameters for
full-field digital mammography. The times until an event of the
natural history of breast cancer were also the same unless modified
by cancer detection. All women underwent biennial screening
from 50 to 69 years of age. Women aged 70 years or older were
followed-up until 2029 only if they were diagnosed with cancer
between the ages of 50 and 69 years or with an interval cancer in
the last mammogram.
The simulation model was implemented by using Arena
(Rockwell Software) version 13.9.
Target population
The target population at the beginning of the simulation
included 100,000 women aged 50-69 years undergoing biennial
screening. Every 2 years, women aged 50–51 years old entered the
target population, following the age structure of the Spanish
population [27]. Women undergoing their last mammogram (aged
68–69) were excluded from the target population unless they were
found to have breast cancer within the screening program or an
interval cancer in the last mammogram (details of the estimation of
the parameters and the simulation are provided in Appendix S1).
Natural history model parameters
Breast cancer incidence [28] was used to estimate the time until
pre-clinical onset [29,30]. The duration of pre-clinical status was
modeled according to age at pre-clinical onset [31], ranging from
2 in 40-year-olds and increasing to 4 years after that age of 50
years (see the appendix S1 for further details).
Age of death from any cause was modeled using the number of
women and the number of deaths, by age, of the Spanish
population in 2008 [27,32].
We assumed that if a woman enters the clinical stage, the cancer
is detected on the basis of symptoms. Currently available data did
not allow modeling the natural history of breast cancer based on
progression through cancer stages, occurrence of symptoms or
recurrences. Thus, the cancer stage was assigned according to the
distributions described in the appendix S1 for screening-detected
and clinically-detected cancers. Survival according to stage and
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age at detection also depended on the birth cohort [33] (see the
appendix S1 for further details).
Screening events
The participation profile for each woman was generated at the
beginning of the simulation in order to ensure the same
participation profile for digital and screen-film screening. Partic-
ipation was treated as a probabilistic parameter (see appendix S1
for details) with values based on a probability of 78.7%for
participation in initial screening and of 83.2% in successive
screenings. When a woman was scheduled to participate in a
screening round, a result was sampled using sensitivity values for
women in the pre-clinical or clinical stage and specificity values for
cancer-free women.
The proportion of false-negative results was obtained from a
study on interval cancers [34]. False-negatives were defined as all
Figure 1. Flow chart of the conceptual model (screening [a] and natural history of cancer [b]). TN: true negative, FP: false positive, TP: true
positive, FN: false negative.
doi:10.1371/journal.pone.0097459.g001
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interval cancers not classified as true interval cancers and included
existing cancers not detected by mammography: false negatives,
occult tumors, and minimal signs, which all together represent
57.5% of false negatives [34]. This percentage was applied to the
overall number of interval cancers in the 20-year period and
sensitivity was calculated. Sensitivity was assumed to be similar for
both techniques [10–13] but was modeled as a probabilistic
parameter and was sampled separately for each technique using
the same statistical distribution with a mode of 86.66%. This
allowed us to obtain scenarios with similar and different
sensitivities favoring digital or screen-film mammography (see
appendix S1).
Specificity was also treated as a probabilistic parameter and was
calculated by stratifying by digital or screen-film mammography as
well as by initial or successive screening, giving results of 88.8% for
digital and 88.3% for screen-film mammography in the initial
round and 95.8% for digital and 95.4% for screen-film screening
mammography in successive rounds [15]. These results coincided
with the mode of the distributions for specificity (see appendix S1)
and also allowed us to obtain scenarios with similar and different
specificities favoring one or other technique.
In breast cancer screening, if a screening result is positive, a
combination of additional (confirmatory) tests is assigned to the
woman. Tests include additional mammographic projections,
ultrasound, fine-needle aspiration cytology (FNAC), core biopsy,
and open surgical biopsy. By using the Breast Cancer Screening
Program database, the relative frequencies of the existing
combinations of tests were calculated, stratifying by digital or
screen-film mammography as well as by initial or successive
screening.
Cancer detection
In our model cancer is detected inside and outside the screening
program. The latter refers to nonparticipating women and interval
cancers. The distribution of cancer stage at detection differs
according to age and the screening round (initial or successive) as
well as according to the detection setting. Clinical detection refers
to cancers detected by clinical symptoms (interval cancers or
cancers in nonparticipating women) and screening detection refers
to those detected through a screening program (participating
women). The stage distribution of screen-detected cancers differed
according to digital or conventional mammography but that of
clinical detected cancers was the same. In all cases, stage
distribution was treated as a probabilistic parameter. See appendix
S1 for more details.
Unitary costs
The study was carried out from the perspective of a National
Health System that includes in its portfolio both preventive
programs and clinical treatments, as it is the case of Spain and the
majority of European countries. That means that the same payer
bears all the preventive and curative costs. The costs of both
screen-film and digital mammography were obtained from the
accounting system of a Spanish program [35] before and after the
process of switching from screen-film to digital mammography.
The cost per woman screened was 39.29J with screen-film and
42.28J with digital mammography. These figures included all the
program costs: human resources, equipment and structure, and
corresponded to year 2009 [35]. Amortization times for equip-
ments (radiological and Picture Archiving and Communication
System - PACS) were set at 10 years following accounting criteria.
The cost of diagnostic and screening mammograms was
assumed to be the same, according to expert opinion. The reason
is that, although a screening mammogram needs to be read by two
T
a
b
le
1
.
C
o
st
s
o
f
ca
n
ce
r
tr
e
at
m
e
n
t
p
e
r
m
o
n
th
,
ca
n
ce
r
st
ag
e
an
d
tr
e
at
m
e
n
t
p
h
as
e
.
In
it
ia
l
p
h
a
se
F
o
ll
o
w
-u
p
A
d
v
a
n
ce
d
p
h
a
se
D
u
ra
ti
o
n
(m
o
n
th
s)
C
o
st
p
e
r
m
o
n
th
D
u
ra
ti
o
n
(m
o
n
th
s)
C
o
st
p
e
r
m
o
n
th
P
ro
b
a
b
il
it
y
o
f
re
cu
rr
e
n
ce
D
u
ra
ti
o
n
(m
o
n
th
s)
C
o
st
p
e
r
m
o
n
th
S
ta
g
e
C
IS
5
.7
5
2
,0
0
6
.2
5
1
1
5
.2
5
1
3
2
.1
0
2
.7
5
I
9
.4
0
2
,0
0
6
.2
5
1
1
1
.6
0
2
9
1
.8
7
7
.8
5
II
1
0
.6
2
2
,2
3
6
.9
2
1
1
0
.3
8
5
7
7
.3
5
1
4
.6
8
III
1
1
.1
1
2
,2
3
6
.9
2
1
0
9
.8
9
7
3
7
.6
5
3
5
.3
8
IV
lif
e
ti
m
e
3
,4
3
8
.7
1
C
IS
:
C
ar
ci
n
o
m
a
in
si
tu
.
Si
m
ila
r
m
o
n
th
ly
co
st
s
o
f
th
e
in
it
ia
l
p
h
as
e
w
e
re
fo
u
n
d
b
e
tw
e
e
n
D
C
IS
an
d
st
ag
e
I,
an
d
b
e
tw
e
e
n
st
ag
e
s
II
an
d
III
.
T
h
e
d
u
ra
ti
o
n
o
f
th
e
fo
llo
w
-u
p
p
h
as
e
in
cl
u
d
e
d
th
e
ti
m
e
fr
o
m
su
rg
e
ry
u
n
ti
l
a
m
ax
im
u
m
o
f
1
0
ye
ar
s,
i.e
.
fo
llo
w
-u
p
w
as
ca
lc
u
la
te
d
as
1
0
ye
ar
s
(1
2
0
m
o
n
th
s)
m
in
u
s
th
e
d
u
ra
ti
o
n
o
f
th
e
in
it
ia
l
p
h
as
e
e
xc
e
p
t
th
e
fi
rs
t
m
o
n
th
.
T
h
e
d
u
ra
ti
o
n
o
f
fo
llo
w
-u
p
fo
r
w
o
m
e
n
as
si
g
n
e
d
to
h
av
e
a
re
cu
rr
e
n
ce
w
as
sa
m
p
le
d
fr
o
m
a
U
n
if
o
rm
d
is
tr
ib
u
ti
o
n
fr
o
m
th
e
e
n
d
o
f
th
e
in
it
ia
l
p
h
as
e
to
th
e
e
n
d
o
f
th
e
fo
llo
w
-u
p
p
h
as
e
.
T
h
e
co
st
s
o
f
m
e
ta
st
at
ic
ca
n
ce
r
w
e
re
si
m
ila
r,
re
g
ar
d
le
ss
o
f
w
h
e
th
e
r
th
e
tu
m
o
u
r
w
as
an
in
it
ia
l
st
ag
e
IV
ca
n
ce
r
o
r
a
re
cu
rr
e
n
ce
.
It
s
d
u
ra
ti
o
n
w
as
fo
r
th
e
lif
e
ti
m
e
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
9
7
4
5
9
.t
0
0
1
Budget Impact of Switching to Digital Mammography
PLOS ONE | www.plosone.org 4 May 2014 | Volume 9 | Issue 5 | e97459
radiologists and needs a higher number of projections, it takes an
average of 3 minutes to read, while a diagnostic mammogram
needs fewer projections and is read by one radiologist but reading
takes longer.
The costs of breast ultrasound, FNAC, core needle biopsy and
open surgical biopsy were obtained from the cost accounting
systems of several Spanish hospitals[36]. Women identified as
having had these procedures in the Breast Cancer Screening
Program were analyzed. The cost of a breast ultrasound was
16.69J. The cost of an FNAC included the cost of the procedure
(80.22J), the cytological analysis of the sample (80.78J) and the
consultation with the surgeon or gynecologist to inform the
woman of the result (142.25J), amounting to 303.25J. The cost of
a core needle biopsy included the procedure (113.54J), the
histological analysis of the sample (14.37J) and the consultation
with the surgeon or gynecologist to inform the woman of the result
(142.25J), amounting to 270.16J. The cost of an open surgical
biopsy was 1,388J [36].
The cost of treatment was obtained from a study [37] that
included incident breast cancer patients from 2000 to 2005.
Patients were followed-up until December 2007 and the costs of
treatment were included in addition to other variables such as
cancer stage. Three different phases were considered for stages
lower than stage IV: initial phase, follow-up and, if there was a
Table 2. Twenty-year cumulative results on health and validation outcomes, according to type of mammogram.
Digital mammography Screen-film mammography
N % N %
Overall data
Invited women 251,960 251,960
Initial population 100,000 100,000
New women entering target population 151,960 151,960
Screening mammograms 731,510 731,506
Initial screening 111,718 15.3% 111,718 15.3%
Successive screening 619,792 84.7% 619,788 84.7%
Recall for further assessment
Recall rate 44,536 6.1% 47,931 6.6%
Further assessments
Additional mammograms 19,085 2.6% 28,529 3.9%
Ultrasound 34,241 4.7% 37,809 5.2%
Fine-needle aspiration cytology 11,812 1.6% 20,729 2.8%
Core biopsy 2,725 0.4% 4,611 0.6%
Open surgical biopsy 302 0.04% 1,544 0.2%
False positive rate 39,833 5.4% 43,226 5.9%
Initial screening 12,812 11.5% 13,275 11.9%
Successive screening 27,021 4.4% 29,951 4.8%
Cancer detection
Cancer detection rate 4,702 0.643% 4,704 0.643%
Carcinoma in situ 1,008 21.4% 841 17.9%
Invasive cancers 3,694 78.6% 3,864 82.1%
Stage I 1,944 41.3% 2,073 44.1%
Stage II 1,380 29.4% 1,230 26.1%
Stage III 350 7.4% 549 11.7%
Stage IV 20 0.4% 13 0.3%
Interval cancer rate 1,588 0.217% 1,587 0.217%
True interval cancers (% of all cancers) 1,271 27.0% 1,271 27.0%
False negatives (% of all cancers) 316 6.7% 316 6.7%
Mortality
Deaths due to cancer 1,887 0.749% 1,942 0.771%
Carcinoma in situ 16 0.9% 14 0.7%
Stage I 444 23.6% 463 23.9%
Stage II 790 41.9% 791 40.7%
Stage III 424 22.5% 519 26.7%
Stage IV 159 8.5% 155 8.0%
doi:10.1371/journal.pone.0097459.t002
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recurrence, advanced phase. For stage IV, only the advanced
phase was considered. For each phase, the mean duration and
mean cost per month were calculated. For stages lower than IV,
the probability of recurrence was also calculated. Within the
model, each woman with a diagnosis of cancer was assigned a
monthly cost, according to the detection stage and treatment
phase. The costs and durations of the phases are shown in Table 1.
Original costs were based on the year 2005 and a cumulative
Consumer Price Index (CPI) of 7.9% was applied to adjust them to
the year 2009.
Probabilistic sensitivity analysis
Crucial parameters such as sensitivity, specificity, the stage
distribution of detected cancers and participation were included as
probabilistic parameters (see Appendix S1 for details on the
distributions assigned). The results of the sensitivity analysis were
stratified according to groups. The groups were created, based on
the detection and recall rate: a group of simulation runs with better
rates for digital mammography and another group with better
rates for screen-film mammography were established. A better
detection rate was defined as a rate at least 0.5% higher and a
better recall rate was defined as a rate of at least 0.5% lower.
Another group was defined by including those runs with a better
detection rate and a higher proportion of noninvasive cancers
detected through screening (at least 1% higher) with digital
mammography.
Simulation analysis of results
Results were analyzed as the mean of 2,000 replications of the
model with independent streams of random numbers. This sample
size was calculated to detect a significant difference in overall costs
at the 0.05 level using preliminary results with 100 replications,
and allowed the results to be stratified for sensitivity analysis. The
time units were years and the simulation horizon was 20 years,
from 2010 to 2029.
The following results were used to validate the model: the
number of invited women through time (by initial and successive
screenings), the participation rate, the mean age of invited women,
the number of mammograms over time (by initial and successive
screenings), the recall rate, cancer detection rate, false-positive
rate, false-negative and interval cancer rate, the distribution of
additional tests, the distribution of cancer stage (pre-clinical and
clinical), and life expectancy. Validation results were shown to the
research team using graphics through time and compared to
published and unpublished data on Spanish programs. The
distributions of the probabilistic parameters were also shown and
its relationship with outcomes explained, as well as published data
from other countries was presented to contextualize the need to
include them as probabilistic parameters. The research team
checked the validation results and the model was considered as
valid, credible and useful for the purposes of the study.
Budget Impact Analysis
Budget impact analysis requires the inclusion of the entire
population involved in a system each year [38]. Thus, individual
Figure 2. Budget impact analysis. Differences in cost between screen-film and digital mammography, by type of cost and year. Positive
differences indicate cost savings with digital mammography.
doi:10.1371/journal.pone.0097459.g002
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women entering and exiting the model were simulated throughout
the simulation horizon. Each year, the impact on the budget was
calculated according to the difference between the two alternatives
(screen-film minus digital) in overall costs, screening costs, and the
costs of additional tests and cancer treatment. The cost results for
each technique and the confidence intervals for the cost differences
were shown for years 2010, 2015, 2020, 2025 and 2029. Costs
were not discounted, according to the published good practices for
budget impact analysis [38].
Results
The model started with a target population of 100,000 women
aged 50–69 years. Over the 20 simulated years, 151,960 women
were dynamically incorporated into the target population, making
a total of 251,960 women invited to the program and resulting in
more than 731,400 screening mammograms, of which 15.3%
corresponding to initial screening (Table 2).
The recall rate was 6.1% for digital and 6.6% for screen-film
mammography. Fewer additional tests were required with digital
mammography (Table 2). The false positive rate was 5.4% for
digital mammography and 5.9% for screen-film mammography.
The cancer detection rate (0.64%), the interval cancer rate (0.22%)
and the mortality rate (about 0.76%) were similar between digital
and screen-film mammography (Table 2).
Table 3 and Figure 2 show the budget impact of digital
mammography in the short and the long term. The cost of the
screening program with digital mammography was always higher
but was offset by the savings due to a lower need for additional
tests. Reductions in treatment costs were an additional saving.
Figure 2 shows the yearly difference between the two screening
modalities. Confidence intervals in Table 3 show significant
savings in overall costs and the costs of additional tests and
treatment in the short and long term. Moreover, the savings in
treatment costs were clear and increased over time. The overall
cost savings were 165,540J (95%CI from 133,253 to 197,827)
after 1 year, 1,115,857J (95%CI from 932,147 to 1,299,567) at 10
years and 2,866,124J (95%CI from 2,492,610 to 3,239,638) at 20
years. This saving represented reductions/reduced costs/savings of
3.0%, 4.5% and 8.1%, respectively, over the overall cost of
screening with screen-film mammography.
Figure 3 shows the results of the sensitivity analysis for the
groups of runs with better detection and recall rates for digital
(n = 921) and for screen-film (n = 469) mammography. Both
groups showed a significant net benefit of digital mammography.
The results of runs with a better detection rate and a higher
proportion of noninvasive cancers with digital mammography
showed higher costs of digital mammography in the short term,
but significant savings in the long term (after the 10th year, data
not shown).
Discussion
The main finding of the budget impact analysis was that a
switch to digital mammography results in net savings if, in addition
to screening costs, the costs of additional tests and treatment are
taken into account, with similar screening results. The model was
run for an initial population of 100,000 women aged 50–69 years,
which, according to the current structure of the Spanish
population, would correspond to an overall population of about
860,000 inhabitants.
Table 3. Budget impact analysis of digital mammography compared with screen-film mammography.
Year
2010 2015 2020 2025 2029
Digital mammography
Overall cost 5,429,104 15,546,355 23,922,992 29,002,023 32,420,266
Screening 1,318,641 1,437,720 1,591,541 1,671,728 1,722,550
Additional tests 254,246 290,016 316,109 328,451 334,096
Cancer treatment 3,856,217 13,818,618 22,015,343 27,001,844 30,363,620
Screen-film mammography
Overall cost 5,594,644 15,996,017 25,038,849 31,190,348 35,286,390
Screening 1,225,388 1,336,029 1,478,975 1,553,505 1,600,717
Additional tests 475,898 542,930 588,531 609,703 629,704
Cancer treatment 3,893,358 14,117,058 22,971,343 29,027,141 33,055,968
Difference (Screen-film - Digital)
Overall cost 165,540 449,662 1,115,857 2,188,325 2,866,124
95%CI [133,253; 197,827] [344,495; 554,830] [932,147; 1,299,567] [1,897,187; 2,479,463] [2,492,610; 3,239,638]
Screening 293,253 2101,692 2112,566 2118,224 2121,833
95%CI [293,517; 292,988] [2101,966; 2101,417] [2112,873; 2112,259] [2118,544; 2117,903] [2122,167; 2121,498]
Additional tests 221,652 252,914 272,423 281,252 295,608
95%CI [217,116; 226,187] [248,017; 257,812] [267,096; 277,750] [275,884; 286,620] [289,974; 301,242]
Cancer treatment 37,141 298,440 956,000 2,025,297 2,692,348
95%CI [5,298; 68,984] [193,516; 403,364] [772,553; 1,139,447] [1,734,283; 2,316,311] [2,319,115; 3,065,582]
CI: Confidence Interval.
doi:10.1371/journal.pone.0097459.t003
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Several studies [4–7] have reported that digital mammography
is more expensive than screen-film mammography. However, the
actual economic impact should take into account all the costs
derived from a population-based screening program, that is, the
costs of confirmatory tests and those of treating detected cancers.
To our knowledge, this is the first study to perform a budget
impact analysis of digital mammography for breast cancer
screening. Previous studies have consisted of cost comparisons
[4,7] and cost-effectiveness studies [5,6] and have included the
costs of screening only. Our results show that the savings due to
fewer additional tests alone offset the higher cost of screening with
digital mammography. In addition, the greatest savings corre-
sponded to treatment costs.
Our model shows that, although the differences in recall rate
between digital and screen-film mammography are small in
magnitude, they result in substantial cost savings in the long term
as the lower recall rate with digital mammography results in fewer
adverse events and additional tests with a consequent reduction in
the negative impact on women. The most frequent additional test
with digital mammography was one ultrasound scan (about 30%),
while for conventional mammography a combination of ultra-
sound and FNAC was used (about 22%). Because the differences
in recall and detection rate between screen-film and digital
mammography are controversial, sensitivity and specificity were
included as probabilistic parameters, meaning that some simula-
tions were run with better sensitivities and/or specificities for
digital mammography, others were run with better sensitivities
and/or specificities for screen-film mammography, other simula-
tions were run combining opposite directions for each parameter
and still others were run with similar parameters. The results of the
sensitivity analysis performed with the results of detection and
recall rates demonstrated that, for all subgroups, the switch to
digital mammography produced significant net savings in the long
term, indicating that our results are consistent and robust
concerning differences in the detection and recall rates between
digital and screen-film mammography. The sensitivity analysis
stratified by excess detection of carcinoma in situ with digital
mammography also showed net savings in the long term (data not
shown), despite excess costs in the short term.
The model’s parameters were mostly obtained from Spanish
breast cancer screening programs that followed the standards of
the European guidelines, thus conferring homogeneity to the
model. However, the parameters related to the natural history of
the disease, such as the sojourn time in the pre-clinical stage,
although adapted to our population, were based on US data.
Treatment costs may have been underestimated because
medication criteria corresponded to 2000–2005 and costs to
2005 and more expensive chemotherapy treatments have been
introduced since then. In addition, treatment costs included those
of women with cancers detected within the simulation horizon
only. Although this consideration did not pose a limitation to our
objective of comparing digital with screen-film mammography
Figure 3. Sensitivity analysis results. DM better (n = 921 runs): Digital mammography higher detection rate and lower recall rate, or digital higher
detection rate and similar recall rate, or digital lower recall rate and similar detection rate. SFM better (n = 469 runs): Screen-film mammography
higher detection rate and lower recall rate, or SFM higher detection rate and similar recall rate, or SFM lower recall rate and similar detection rate.
Intermediate scenario (n = 610 runs, not shown): Digital higher detection rate and SFM lower recall rate, or digital lower recall rate and SFM higher
detection rate, or both similar detection and recall rates. CI: Confidence Interval.
doi:10.1371/journal.pone.0097459.g003
Budget Impact of Switching to Digital Mammography
PLOS ONE | www.plosone.org 8 May 2014 | Volume 9 | Issue 5 | e97459
screening, it did lead to underestimation of treatment and overall
costs, especially in the short term.
Given that our objective was to compare the population-based
screening program using one technology versus the same program
using the other, the costs and inefficiencies associated to the
process itself of switching from screen-film to digital mammogra-
phy have not been included [39]. Further research would be
needed to estimate the economic impact of the process of change
and how increased short-term costs may hamper implementation
of digital mammography throughout all the Spanish screening
units.
In conclusion, switching from screen-film to digital mammog-
raphy within a population-based breast cancer screening program
reduces expense in the long term in addition to providing technical
advantages. The higher expense of digital screening is offset by the
reduction in additional tests. These results were consistent across
distinct scenarios representing the different results obtained in
European breast cancer screening programs.
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